American Century Companies Inc. boosted its position in Bio-Techne Corp (NASDAQ: TECH) by 78.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,037,806 shares of the biotechnology company's stock after buying an additional 894,987 shares during the
Citigroup Inc. trimmed its stake in shares of Bio-Techne Corp (NASDAQ: TECH) by 33.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 197,392 shares of the biotechnology company's stock after selling 97,843 shares during the period. Citigroup Inc. owned
CMB.TECH NV (CMBT) Q4 2025 Earnings Call Transcript
CMB.TECH ANNOUNCES Q4 2025 RESULTS EIGHT VLCCS SOLD AT STELLAR PRICES ANTWERP, Belgium, 26 February 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the fourth quarter ended 31 December 2025. HIGHLIGHTS Financial highlights: Profit for the period of USD 90.1 million in Q4 2025.
MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 46th Annual Health Care ConferenceMarch 3, 202611:10 AM EST Leerink Partners Global Healthcare ConferenceMarch 10, 20268:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its position in Bio-Techne Corp (NASDAQ: TECH) by 95.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,612 shares of the biotechnology company's stock after selling 59,110 shares during the quarter. BNP PARIBAS
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on time Provides confidence for use in clinical trials and in-house test development MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.
Caprock Group LLC purchased a new position in Bio-Techne Corp (NASDAQ: TECH) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,302 shares of the biotechnology company's stock, valued at approximately $1,710,000. Several other hedge funds have also recently modified their holdings
Antwerp, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its fourth quarter 202 5 earnings prior to market opening on Thursday 26 February 202 6 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment.
Baader Bank Aktiengesellschaft boosted its stake in shares of Bio-Techne Corp (NASDAQ: TECH) by 57.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 103,905 shares of the biotechnology company's stock after buying an additional 38,082 shares during the period. Baader Bank Aktiengesellschaft owned approximately
Antwerp, Feb. 09, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs : CMBTO) has sold two vessels, generating a capital gain of approximately 98.2 million USD in total. Euronav CMB.TECH has sold two VLCCs: Ingrid (2012, 314,000 dwt) and Ilma (2012, 314,000 dwt). The sale will generate a capital gain of approximately 98.2 million USD in Q2 2026, based on the net sales price and book values. The vessels will be delivered to their new owner in Q2 2026.
Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) shot up 7% on Wednesday following a better than expected earnings announcement. The company traded as high as $69.92 and last traded at $69.16. 2,958,199 shares were traded during trading, an increase of 21% from the average session volume of 2,450,796 shares. The stock had previously
Adjusted EPS: $0.46, up 10% year-over-year.GAAP EPS: $0.24, up from $0.22 in the prior year period.Total Revenue: $295.9 million, flat year-over-year on both a
Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript
Bio-Techne tops Q2 EPS and revenue estimates as operating margin jumps 244 bps, even with flat organic sales and a slight year-over-year revenue dip.
While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Techne (TECH) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago.
Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development.